← All trials
NCT06572618
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 11, 2025
- Primary completion
- Feb 19, 2026
- Completion date
- Feb 19, 2026
- First posted
- Aug 27, 2024
- Last posted
- Aug 27, 2024
- Enrollment
- 27
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- City of Hope National Medical CenterLead sponsor
- National Cancer Institute (NCI)Collaborator
- City of Hope National Medical CenterOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.